Coupled-plasma filtration and adsorption for severe burn patients with septic shock and acute kidney injury treated with renal replacement therapy by Mariano, F. et al.
Coupled-plasma filtration and adsorption for severe
burn patients with septic shock and acute kidney
injury treated with renal replacement therapy
Filippo Mariano a,d,*, Zsuzsanna Hollo’ a, Nadia Depetris b,
Valeria Malvasio c, Alberto Mella a, Daniela Bergamo a, Anna Pensa c,
Maurizio Berardino b, Maurizio Stella c, Luigi Biancone a,d
aNephrology, Dialysis and Transplantation U, Department of General and Specialized Medicine, City of Health and
Science, CTO Hospital, Turin, Italy
bAnesthesia and Intensive Care 3, Department of Anesthesia and Intensive Care, City of Health and Science,
CTO Hospital, Turin, Italy
c Plastic Surgery and Burn Center, Department of General and Specialized Surgery, City of Health and Science,
CTO Hospital, Turin, Italy
dDepartment of Medical Sciences, University of Turin, Turin, Italy
a b s t r a c t
Background: Coupled-plasma filtration adsorption (CPFA) is a sorbent-based technology
aimed at removing soluble mediators of septic shock. We present our experience on the use
of CPFA in septic shock severe burn patients with acute kidney injury (AKI) needing renal
replacement therapy (RRT) with the main goal to evaluate efficacy and safety of CPFA in this
specific subset of septic shock patients.
Methods: In this observational study, we retrospectively reviewed the medical notes of all
burn patients admitted to our adult Burn Center who received CPFA, as part of the septic
shock treatment requiring RRT, between January 2001 and December 2017 (CPFA group).
We compared CPFA group with all the burn patients admitted to our Center in the same
period of time, with the same range of relevant clinical characteristics, who developed AKI
and were treated with RRT, but not CPFA (control group). We collected demographic
characteristics, burn size, Sequential Organ Assessment Failure (SOFA) score, microbiolog-
ical data, and patient outcome, in terms of in-hospital mortality rate and the probability of
survival calculated using the revised Baux score. We also collected data regarding CPFA
safety (hemorrhagic episodes, catheter associated-complications, hypersensitivity reac-
tions) and efficiency (number and duration of CPFA sessions, plasma treated amount, plasma
processed dose).
Results: 39 severe burn patients were treated with CPFA (CPFA group) (mean age 46.0 years,
range 40.056.0 years; mean burn size 48.0% TBSA, range 35.060.0% TBSA), and 87 patients







Abbreviations: CPFA, Coupled plasma filtration and adsorption; AKI, Acute kidney injury; CRRT, Continuous renal replacement therapy;
MAP, Mean arterial pressure; TBSA, Total body surface area; MRSA, Methicillin resistant staphylococcus aureus; RRT, Renal replacement
therapy; RCA, Regional citrate anticoagulation.
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treated with RRT, but not CPFA, who had similar clinical characteristics (control group).
Observed mortality rate was 51.3% in the CPFA group and 77.1% in the control group (p 0.004).
Regarding factors affecting survival in the CPFA group, SOFA score on the 1st day of CPFA
resulted significant (OR 2.016, 95% CI, 1.2213.326; p < 0.004) in the multivariate analysis
logistic model.
Conclusions: CPFA treatment for burn patients with AKI-RRT and septic shock, sustained by
bacterial strains non or poorly responsive to therapy, was associated with a lower mortality
rate, compared to RRT alone. However, further research, such as large prospective studies, is
required to clarify the role of CPFA in the treatment of burns with septic shock and AKI-RRT.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Coupled-plasma filtration adsorption (CPFA) is a sorbent-
based technology with an extra-corporeal circuit consisting of
a plasma filter, a resin cartridge and a high-flux dialyzer [1].
CPFA is aimed at removing soluble endogenous inflammatory
mediators circulating in septic shocks and acute kidney
injuries (AKI) via an extracorporeal treatment [1,2]. CPFA pilot
applications in human septic shock demonstrated favorable
effects, by improving hemodynamic status, reducing norepi-
nephrine requirement, and showing immunomodulation
properties [35].
In burn patients, AKI requiring renal replacement therapy
(AKI-RRT) during septic shocks represents one of the most
prejudicial complications, still burdened by a high mortality
rate [616]. CPFA has been described as a promising
emerging purification technique in burns, although there
is no large study reporting its application in burn patients so
far [14].
After a preliminary experience of good hemodynamic
tolerance and metabolic management in burns patients
[17,18], starting in January 2001, we used CPFA as an adjunctive
modality for severe burn patients with septic shock, AKI-RRT
and no clinical response to an appropriate antibiotic therapy.
In this study we present our experience on the use of CPFA
in 39 severe burn patients with septic shock and AKI needing
RRT with the main goal to evaluate efficacy and safety of CPFA
in this specific subset of septic shock patients. Furthermore,
we present and examine aspects of the adopted CPFA
technique.
2. Material and methods
2.1. Study design
In this observational study, we retrospectively reviewed the
medical notes of all burn patients admitted to our adult Burn
Center who received CPFA, as part of the septic shock
treatment requiring RRT, between January 2001 and December
2017 (CPFA group).
In order to better evaluate efficacy and safety of CPFA, we
compared CPFA group with all the burn patients admitted to
our Center in the same period, with the same range of relevant
clinical characteristics, who developed AKI and were treated
with RRT, but not CPFA (control group).
We collected demographic characteristics, burn size in
terms of % of total body surface area (TBSA) burned, Sequential
Organ Assessment Failure (SOFA) score, frequency of mechan-
ical ventilation treatment, microbiological data, and patient
outcome, in terms of in-hospital mortality rate. Regarding
SOFA score, brain injury was excluded for all patients in the
CPFA group at Burn Center admission, and all of them were
sedated the day that CPFA started. As suspension of sedation
was not possible for safety reasons, the SOFA score of the
central nervous system was conventionally considered +1.
The probability of survival was calculated in each patient
using the revised Baux score [19].
We also collected data regarding CPFA safety (hemorrhagic
episodes, catheter associated-complications, hypersensitivity
reactions) and efficiency (number and duration of CPFA
sessions, and plasma processed dose).
The study was conducted according to the Helsinki
Declaration and approved by the Ethics Committee of our
Hospital (dossier n. CS2/908). Informed consent to the
proposed treatments and the consent to retrospectively
review the medical notes and analyze the collected data
was obtained from the patients or substitute decision-makers.
2.2. Management of septic shock and AKI
Systemic treatment of burn patients and diagnosis and
treatment of septic shock was managed by a multidisciplinary
team on the basis of guidelines in place at that time [2028].
RRT was started when patients were in a trend of fluid
overload not responsive to conservative management includ-
ing maximal diuretic therapy and: (1) oliguria or (2) severe
hyperkalemia, or (3) severe acidosis or (4) uremic complica-
tions [20].
CPFA was chosen as an additional therapy when: (1) the
patients were in septic shock with AKI-RRT and multiorgan
failure, and: (2) microbiological confirmation of the septic
event by means of blood cultures was positive for multidrug-
resistant strains, and: (3) there was no clinical response after
72 h of appropriate antibiotic treatment.
2.3. CPFA technique
CPFA was performed with a dedicated machine that the
manufacturer updated over time (Multimat B.IC/Lynda/Am-
plya, Bellco spa, Mirandola, Italy). CPFA was always carried out
by using a polyethersulfone plasma filter (0.5 m2, MPS 05,
Bellco) placed in series with a highly permeable
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polyethersulfone hemodialyzer (1.4 m2, BLS814 G, Bellco).
Plasmafiltrate was adsorbed on an unselective hydrophobic
resin cartridge (140 ml for 70 g, with a surface of about 700 m2/g)
[1,17,18].
According to CPFA protocol, blood flow rate ranging from
100 to 180 ml/min and effluent rates were set by the target of
dialysis adequacy. Following the manufacturer instructions
over time the effluent resulted from hemodialysis, hemodia-
filtration, or hemofiltration modalities [1,5,17,18]. We set an
exchange of 34 l/hour of effluent at the start to achieve an
amount of 3042 l/day, accomplishing the dialysis target of 20
25 ml/kg/die [20]. This target was irrespective of the patient’s
residual renal function and dialysate/infusion proportion.
Moreover, as these rates were occasionally limited by the
efficiency and patency of the vascular access, a dedicated
nurse recorded the effective flow rates. According to the
manufacturer’s protocol, plasma filtration rate was main-
tained between 1525% of blood flow rate.
The vascular access of CPFA was provided by 12 F double
lumen venous catheter inserted in the jugular or femoral vein.
2.4. Anticoagulation strategies
In order to provide CPFA effectively and safely, either
unfractionated heparin or citrate were used for anticoagula-
tion of the extracorporeal circuit, on the basis of the patient-
s’characteristics, with the support of our previous experiences
[13,17,18]. Specifically, the regional citrate anticoagulation
(RCA) strategy was preferred if the patient presented (1) a high
bleeding risk (defined as bleeding alert in insertion site
catheter, or at tracheostomy, or gastrointestinal tract or in
surgical wounds) or (2) frank bleeding necessitating transfu-
sion of packed red blood cells [13,17,18]. If none of these
conditions existed, anticoagulation was performed with
unfractionated heparin.
If RCA was applied, an ACD-A dispersed solution was
infused in predilution mode prepared by nurses immediately
before CPFA sessions, or with a specific bag (Citrate, Hospital
Service, Scarmagno, Italy: composition (in mmol/l) Na+148; K
+1.5; Mg++ 0.75; Cl 108; citrate 10; glucose 5.5; bicarbonate 10)
[13,17,18]. Subsequently, after 2012 citrate anticoagulation
was carried out through a citrate-containing bag following the
manufacturer’s instructions (Prismocitrate 18/0, Baxter Italia,
Rome, Italy: composition (in mmol/l) Citrate 18; Na+ 140; Cl
86). A standard sterile bicarbonate-containing solution was
used with calcium as an infusion (Prismasol 32, Hospal,
Mirandola, MO, Italy) or without calcium as dialysate (CiCa,
Fresenius Medical Care, Bad Homburg, Germany).
In all patients, a commercial 10% calcium chloride solution
was infused by the monitor heparin pump in a separate line at
the end of the venous circuit [17,18].
If anticoagulation was achieved with unfractionated
heparin, the latter was administered pre-filter and standard-
ized to an initial bolus of 1250 U followed by 1000 U/h.
Subsequent adjustments were made accordingly to obtain
coagulation parameters of PTT > 60 s. A standard sterile
bicarbonate-containing solution was used in the form of a
dialysate/infusion (Prismasol 32, Hospal, Mirandola, MO, Italy;
composition (mmol/l) Na+ 140; K+ 2.0; Ca++ 2; Mg++ 0.75 Cl: 108;
bicarbonate 32; acetate 4; glucose 5.5).
2.5. Statistical Analysis
Continuous data are expressed as median with quartiles (the
25th and 75th percentiles), and categorical data as frequencies
and percentages. Student T-test, Fisher’s exact test or ANOVA
with multicomparison NewmanKeuls test were used when
appropriate. Multivariate analysis was performed using logis-
tic regression for the total number of nonsurvivor patients to
determine the effect on the in-hospital mortality rate of the
following variables of interest: age, and SOFA score at the start
of CPFA.
KaplanMeier estimate of survival was constructed to
compare 180-day survival between the patients treated with
RCA and those treated with unfractionated heparin anti-
coagulation. Cox’s F-test was used to test the difference in
survival rates.
p < 0.05 value was considered statistically significant.
Statistical computing and graphics were performed by
Statistica v.10.1 (Statsoft, Tulsa, OK, USA).
3. Results
From January 2001 to December 2017, among the 212 patients
who underwent RRT, 39 of them were additionally treated
with CPFA (CPFA group), out of 1520 severe burn patients
admitted to our Burn Center. We identified 87 patients
(Control group) who were treated with RRT, but not CPFA, in
the same period of time, and had showed no significant
differences in terms of burn size, revised Baux score, gender,
septic shock incidence, requirement of mechanical ventila-
tion and time interval from admission to starting of CPFA or
RRT (Table 1).
The overall observed mortality rate was 51.3% in the CPFA
group and 77.1% in the Control group (p 0.004).
3.1. CPFA treatment
In the group CPFA, patients were aged 46.0 years (40.056.0;
median, the 25th and 75th percentiles, range 1481 years) with
a burn size of 48.0% TBSA (35.060.0, range  85%). The median
period between patients’ admission and the onset of sepsis
was 5.5 days (4.57.0). The median period between patients’
admission and RRT start was 15.0 days (7.023.0).
The main reasons for starting an RRT treatment were fluid
overload and oliguria (26 patients, 66.6%), followed by severe
hyperkalemia (18 patients, 46.1%) and severe acidosis (16
patients, 42.0%), and uremic complications (3 patients, 7.6%).
Most of patients of the CPFA and control groups were treated
with potentially nephrotoxic drugs (aminoglycosides, colistin,
vancomycin), and none of the patients underwent contrast-
media procedures. No significant difference was found
between the 2 groups in the use of nephrotoxic drugs, lactate
levels, dose of vasopressors and SOFA score at the onset of
treatment, time from shock to renal failure and overall RRT
treatment duration (Table 1).
In 16 CPFA patients no comorbidities were found. In the
remaining 23 patients, comorbidities included 6 cases of major
psychiatric disorders, 5 cases of polytrauma, 3 cases of chronic
hepatitis, 4 cases of chronic pulmonary obstructive disease
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(COPD), 6 cases of hypertension and 2 cases of diabetes. The
overall prevalence of the above comorbidities in the CPFA
group was not significantly different from that in the control
group (p 0.4045).
Among a total of 70 positive cultures isolated from these
patients’ blood and other specimen sources the gram-negative
strains were predominant (47/70 cultures). The top 6 micro-
organisms were Acinetobacter Baumanni (21 specimens),
Pseudomonas Aeruginosa (16 specimens), Staphylococcus
Aureus MR (6 specimens), Candida spp. (6 specimens),
Coagulase Negative Staphylococcus (5 specimens) and Sten-
otrophomonas Maltophilia (4 specimens).
As shown in Table 2, non survivors were significantly older
in the CPFA group (54 vs. 46 years, p 0.012), and had
significantly higher SOFA score (13.0 vs. 11.0, p 0.005) and
revised-Baux score (119.9 vs. 103.0, p < 0.041). No significant
difference was found for burn size, days of CPFA and
continuous RRT (CRRT), and CPFA dose. While searching for
factors affecting survival in the CPFA group, we included the
two following predictors in the multivariate analysis logistic
model: SOFA score on the 1st day of CPFA, and age. Of these two
predictors, SOFA score was significant (OR 2.016, 95% CI, 1.221
3.326; p < 0.004), whereas p-value for age showed a trend
towards significance (OR 1.065, 95% CI, 0.9971.139; p < 0.059).
Fig. 1 shows the clinical trend of hemodynamics (mean
arterial pressure (MAP), heart rate and norepinephrine
requirement), metabolic indexes (plasma lactate and pH)
and SOFA score for nonsurvivor and survivor patients before
and after initiation of CPFA therapy. Lower values of MAP and
pH, and higher norepinephrine requirements and lactate
plasma levels were observed in nonsurvivors (Fig. 1). In
survivors patients we observed a trend towards a progressive
improvement of the hemodynamic and laboratory param-
eters. Nine patients died within the 2nd day of CPFA.
Regarding anticoagulation strategies, no significant differ-
ences were found for observed mortality rate, revised Baux
score, SOFA score, CRRT days post-admission and number of
CPFA sessions/patient performed, (Table 3). However, the
patients that were treated with unfractionated heparin anti-
coagulation were younger and with higher burn size, whereas
those that were treated with RCA were older (p < 0.05) and with
lower burn size (p 0.06, Table 4).
Survival analysis by KaplanMeyer curves showed a trend
towards a better survival for patients that were treated with
RCA in comparison to those treated with unfractionated
heparin, even though not significant (p 0.1583, Cox’s F-test,
Fig. 2).
Regarding CPFA flow rates, the session duration was
significantly longer for patients treated with RCA, as well as
the amount of effluent volume and net fluid removal. The
median dose of plasma processed during CPFA, normalized to
patient weight, was similar in the two groups (Table 4).
4. Discussion
Severe burn patients represent a specific model of AKI associated
septic-shock in which the severity of the initial insult can be
quantified in terms of burn size and revised Baux score, and the
septic process develops predictably [12,16,2529]. Moreover,
Table 1 – Demographic characteristics of 39 septic shock burn patients with AKI treated with CPFA (CPFA group) and of 87
burn patients treated with only RRT (Control group).a
CPFA groupb Control groupc p
Patients (n) 39 87 
In-hospital mortality (%, n) 51.3%, 20 77.1%, 67 0.004
Age (years) 46.0 (40.0-56.0) 61.0 (46.0-73.0) 0.003
Total body surface area (%) 48.0 (35.0-60.0) 40.0 (30.0-60.0) 0.250
Revised Baux score 111.2 (99.5-126.4) 121.7 (102.9-133.4) 0.118
Gender ratio (male%, n) 74.3%, 29 60.9%, 53 0.102
Septic shock (%, n) 100%, 39 91.9%, 80 0.337
Mechanical ventilation (%, n) 100%, 39 94.2%, 82 0.223
CPFA-RRT/RRT interval (days post-admission) 17 (9-25) 18 (10-28) 0.268
Septic shock/AKI interval (days) 5 (4-7) 5 (3-10) 0.938
CPFA-RRT/RRT duration (days) 5 (3-13) 10 (18-5) 0.111
Citrate anticoagulation (%, n) 51.3%, 20 75.8%, 66 0.012
SOFA score (at 1st day of treatment) 12 (10-14) 12 (10-14) 0.364
Lactate (mmol/l, at 1st day of treatment) 2.0 (1.4-2.5) 2.4 (1.5-3.7) 0.127
Norepinephrin (ug/kg/min, at 1st day of treatment) 0.40 (0.20-0.57) 0.40 (0.20-0.60) 0.762
Nephrotoxic drugs (%, n) 69.3%, 27 66.7%, 58 0.773
Aminoglycosides 56.4%, 22 52.8%, 46 0.708
Colistin 30.8%, 12 21.8%, 19 0.278
Vancomycin 30.8%, 12 26.4%, 23 0.610
Data are given as median (the 25th and 75th percentiles) or as percentage when appropriate. Student T-test or Fisher’s exact test was done when
appropriate.
a Control group (n 87) included all the burn patients treated with RRT from 2000 to 2017, with: (1) a time interval from admission to RRT  5 days, and
(2) the range values of age of 14 and 81 years; and (3) %TBSA range of 85%.
b CPFA = coupled-plasma filtration adsorption with renal replacement therapy.
c RRT = renal replacement therapy alone.
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despite the improvements of supportive intensive care and the
optimization of dialytic techniques, AKI in burn sepsis is still
associated with a high risk of death [616].
It has been hypothesized that CPFA in burn patients could
exert a beneficial immunomodulatory effect [14], being able to
remove exogenous and endogenous inflammatory mediators
through a plasma adsorption mechanism [13]. Nevertheless,
there is no clear demonstration of a survival benefit from CPFA,
so far. However, very few studies have addressed the clinical
impact of CPFA on mortality rates, and the enrolled patients
had septic shock of multifactorial etiology [5]. The selection of
patients may be crucial for demonstrating the efficacy of the
treatment. Even if it was recently shown that two sessions of
CPFA in severe burn patients, in addition to routine treatment,
significantly decreased the level of different cytokines [30], no
study has addressed the issue of CPFA clinical efficacy in a
selected and specific population, such as septic shock severe
burn patients.
Considering the possible benefits and, at the same time, the
lack of evidence, we decided to introduce CPFA as an
Fig. 1 – Outcome of MAP, heart rate, norepinephrine requirement, pH, blood lactate and SOFA score in the first six days of CPFA
for Nonsurvivor (n 20 patients) and Survivors patients (n 19 patients). Data were taken at the start of CPFA day session. Data of
Day 1 were the baseline data at time 0 of CFFA course. The number on the columns indicates the number of considered cases at
each time. The Nonsurvivor patients were: 20 at day 1, 15 at day 2, 11 at day 3, 10 at day 4, 8 at day 5, and 8 at day 6.
Data are given as median (the 25th and 75th percentiles). ANOVA and post-hoc analysis with NewmanKeuls multicomparison
test was done between Nonsurvivor and Survivors patients (*p < 0.05). MAP = mean arterial pressure.
Table 2 – Characteristics, clinical parameters and outcome of non survivor and survivor patients treated with CPFA (CPFA
group).
Non survivor Survivor p
Patients (n) 20 19
Age (years) 54 (4371) 46 (3051) 0.012
Total body surface area (%) 49 (3565) 45 (3560) 0.815
Revised Baux score 119.9 (105.9131) 103.0 (94.8120.5) 0.041
Gender ratio (male%, n) 65.0%, 13 76.1%, 16 
Mechanical ventilation (%, n) 100, 20 100, 19 
SOFA score (at 1st day of CPFA) 13 (1214) 11 (911) 0.005
Cardiovascular 4 (44) 4 (44) 0.547
Respiratory 3 (23) 2 (13) 0.031
Hematologic 1 (02) 0 (01) 0.045
Liver 2 (12) 1 (12) 0.147
Citrate anticoagulation (%, n) 45.0%, 9 57.8%, 11 
CPFA (sessions) 3.5 (1.57) 6 (410) 0.205
CPFA dose (l/kg/day) 0.179 (0.1610.196) 0.171 (0.1380.180) 0.135
CRRTa (days) 10.5 (317.5) 10 (720) 0.892
CRRT intervala (days post-admission) 16.5 (824.5) 18 (1328) 0.907
Data are given as median (the 25th and 75th percentiles) or as percentage when appropriate. Student T-test or Fisher’s exact test was done when
appropriate.
a Days of CRRT are referred to days of treatment of only CRRT done before or after the cycle of CPFA-RRT days.
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adjunctive therapy only for severe burn patients with a poor
prognosis, such those suffering from septic shock with multi
organ failure sustained by multi-drug resistant bacterial
strains not or poorly responsive to antibiotic therapy.
In the CPFA group the mortality rate was 51.3%, lower than
the mortality rate in the control group treated only with RRT,
and better in comparison to the literature data [613,16]. This
result suggests that CPFA in burn patients with severe septic
shock and concomitant AKI could provide an actual benefit on
the outcome when compared to standard CRRT treatment.
We applied logistic regression analysis on our data,
searching for factors that help predict the survival of patients
treated with CPFA. We found that the SOFA score was the
only significant parameter, whereas the age was near
significance. As also suggested by the significantly higher
value in nonsurvivors than in survivors, the SOFA score
(Table 2 and Fig. 1) confirmed to be a reliable predictor of the
outcome for burn patients [24,31,32]. In the same way, the
observed high lactate levels in the first four days of CPFA,
when mortality peaked (see Fig. 2) reflected the fatal
outcome and confirmed lactate as a strong predictor of
mortality in septic shock burn patients [33]. As shown in
Fig. 1, the CPFA patients of both groups had slightly elevated
levels of lactate, while having an extremely high mean SOFA
score of >12. This puzzling discrepancy could be due to some
specific conditions of burn patients, such as infection and
organ dysfunction lasting a long time, the pathogenesis
sustained by different microorganisms and the fluctuating
course of infective process. In addition, we analyzed the
presence of comorbidities [32,33]. We did not find a
difference of overall comorbidities prevalence between the
two groups, thus making the comparison reliable.
As expected, the patients of both groups experienced an
intensive use of potentially nephrotoxic antibiotics. Therefore,
the AKI pathogenesis of our patients was likely to be
multifactorial. Besides immunological and infectious factors
[29], AKI reflected also a direct tubular antibiotic toxicity, and
both systemic and local hemodynamic derangements.
Table 4 – CPFA group flow rates according to anticoagulation protocol with Citrate (n 20 patients) and Heparin (n 19 patients)
subgroups.
All Citrate-CPFA Heparin-CPFA pa
CPFA sessions 238 128 110 
Sessions (no./patient) 5 (28) 5 (210) 5 (37) 0.945
Duration of CPFA session (hours) 8.0 (7.09.0) 8.0 (7.010.0) 7.5 (7.08.0) 0.005
Hemorrhagic episodes 6/238 0/128 6/110 0.005
Catheter-related complications 7/41 2/18 5/23 0.327
Hypersensitivity reactions 0/238 0/110 0/128 
Blood flow rate (ml/min) 150 (140160) 150 (140165) 150 (150160) 0.654
Circuit citratemia (mmol/l)  3.9 (3.44.5)  
Unfractionated heparin (Units/hour)   900 (7501200) 
Effluent volume (l/session) 22.5 (19.527.0) 25.2 (21.633.6) 21.0 (18.024.0) 0.005
Net fluid removal (l/session) 0.20 (0.001.10) 0.70 (0.001.10) 0.20 (0.000.85) 0.024
Plasma-treated (l/session) 12.2 (10.414.6) 12.6 (10.416.3) 12.1 (10.113.4) 0.006
Plasma-processed dose (l/kg/day) 0.175 (0.1440.198) 0.176 (0.1440.202) 0.174 (0.1450.196) 0.854
Data are expressed as median (the 25th and 75th percentiles).
a Student T-test or Fisher exact test was done between Citrate and Heparin groups when appropriate.
Table 3 – Demographic characteristics of 39 severe burn septic shock patients undergoing CPFA (CPFA group). Data were
given according to anticoagulation protocol with Citrate (n 20 patients) and Heparin (n 19 patients).
Citrate-CPFA Heparin-CPFA
All Dead Alive All Dead Alive pa
Patients (n) 20 9 11 19 11 8 0.314
In-hospital mortality (%) 45.0 %   61.1 %   
Age (years) 50.5 (4362) 55 (4678) 46 (4055) 44 (3156) 45 (3760) 37 (4047) 0.049
Total body surface area (TBSA,%) 45 (3552.5) 45 (3555) 45 (35k50) 56 (4065) 50 (40-80) 58 (4260) 0.062
Revised Baux score 108 (99122) 114 (103126) 104 (99121) 117 (90131) 124 (108-138) 102 (88116) 0.756
SOFA score (on the 1st day of CPFA) 13.0 (913) 13.0 (1215) 10.5 (913) 11.5 (1014) 13.0 (1114) 10.5 (911) 0.929
Gender ratio (male%, n) 70.0%, 14 44.4%,4 90.9%, 10 78.9%, 15 81.8%, 9 75.0%, 6 0.397
Mechanical ventilation (%, n) 100%, 20 100%, 10 100%, 10 100%, 19 100%, 11 100%, 7 
CRRT interval (days post-admission) 18.5 (929.5) 21 (728) 18 (931) 15 (921) 12 (821) 17 (1424) 0.387
Data are given as median (the 25th and 75th percentiles).
a Student T-test or Fisher’s exact test was done between Citrate (all cases) and Heparin (all cases) anticoagulation protocol when appropriate.
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We further explored some technical aspects of the CPFA
technique. Specifically, we wanted to see if the anticoagulation
strategy adopted in delivering CPFA could influence the
efficacy and safety of the treatment. The patients treated
with unfractionated heparin anticoagulation and those
treated with RCA had similar characteristics, even tough
patients treated with unfractionated heparin coagulation were
younger and had higher burn size. The observed mortality did
not significantly differ between the two groups, even if the
KaplanMeyer curves of survival showed a better trend for
patients treated with RCA strategy (Cox’s F-test p 0.1583).
However, as previously described in continuous extracorpo-
real treatment [13,17,18], during regional unfractionated
heparin anticoagulation hemorrhagic events were more
frequent.
In the present paper we reported our clinical experience
with a new treatment option for a specific ICU population, such
as burn patients with septic shocks and poor outcome, and this
could be the strength of our study, and likely one possible
reason for the positive results. The improved survival rate is
indeed far from being conclusive and should be considered as a
starting point for further studies. CPFA in burn patients with
severe septic shock and concomitant AKI could provide an
actual benefit on the outcome when compared to standard
CRRT treatment. According to other experiences, these data
also suggest that the actual benefit demonstration of a new
treatment option in ICU patients is deeply related to the choice
of appropriate patients, with appropriate indications [34].
We recognize that our study has some limitations. First,
severe burn patients suffer from a complex condition, and they
undergo multiple interventions. Isolating the effect of a single
treatment on the outcome could be impossible. Secondly, the
number of subjects is limited in such specific population, and
treated over an extended period of time when comprehensive
burn care measures and team expertise have improved.
Thirdly, as suggested by the high number of deaths in the
first 48 h, the mortality rate could have been reduced with an
earlier CPFA treatment. This consideration was also supported
by the strong correlation of the SOFA score as a good predictor
of fatal outcome.
5. Conclusion
CPFA treatment for burn patients with AKI-RRT and septic
shock, sustained by bacterial strains non- or poorly responsive
to therapy, was associated with a lower mortality rate
compared to RRT alone. However, further research, such as
large prospective studies, is required to clarify the role of CPFA
in the treatment of burns with septic shock and AKI-RRT.
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